Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX) had its price objective cut by D. Boral Capital from $12.00 to $4.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also issued reports on QNCX. Brookline Capital Management began coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price for the company. Oppenheimer started coverage on shares of Quince Therapeutics in a report on Monday. They set an “outperform” rating and a $10.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $8.00.

Quince Therapeutics Price Performance

Shares of QNCX stock opened at $1.37 on Tuesday. The firm’s 50 day moving average price is $1.49 and its two-hundred day moving average price is $1.44. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The stock has a market cap of $60.28 million, a PE ratio of -1.10 and a beta of 0.71.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The firm had revenue of $0.17 million during the quarter. As a group, analysts forecast that Quince Therapeutics will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently modified their holdings of QNCX. Geode Capital Management LLC raised its holdings in Quince Therapeutics by 24.2% during the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock worth $263,000 after buying an additional 66,170 shares during the period. Anfield Capital Management LLC bought a new stake in shares of Quince Therapeutics during the fourth quarter worth $50,000. Scharf Investments LLC acquired a new stake in shares of Quince Therapeutics during the fourth quarter worth $170,000. Two Sigma Investments LP bought a new stake in Quince Therapeutics in the 4th quarter valued at $57,000. Finally, Northern Trust Corp lifted its position in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares in the last quarter. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.